GLP-1 medications work by turning down appetite. For most people, that's the point. But if you have a history of an eating disorder, or you're living with one now, "eats less, thinks about food less, loses weight quickly" is not a neutral description. It reads like a list of the features you may have worked hard to recover from. So it's reasonable to ask before you start: is this safe for someone like me? The evidence is early and mixed. It says less about a simple yes or no than about who needs to be involved in the decision with you.
The concerns
The worry isn't imaginary. GLP-1 medications reduce hunger and increase fullness. If you have a history of restriction (as in anorexia nervosa or restrictive disordered eating), a medication that makes eating less feel effortless can quietly reinforce the patterns recovery was meant to interrupt. What looks like a "good response" to the drug (smaller portions, less interest in food, falling weight) can be hard to tell apart from a relapse.
Rapid weight loss brings its own risk. Losing weight fast can sharpen preoccupation with the body, and changes some people notice on a GLP-1, such as loose skin or facial thinning, can cause distress, especially if body image has been a struggle before. If you're not sure whether what you feel is normal adjustment or something more, our guide on body-image lag versus body dysmorphia walks through the difference. A history of disordered eating makes it more likely that fast change hits hard.
What the research shows so far
The picture isn't all caution, and the harm shouldn't be overstated either. Most of the research signal is at the other end of the eating-disorder spectrum: binge eating disorder (BED), the most common eating disorder, which involves repeated loss-of-control eating, not restriction.
A 2026 systematic review and meta-analysis found that liraglutide (a GLP-1 medication) reduced binge frequency in binge eating disorder compared with placebo. The authors stress that the certainty of evidence was low and the findings only generate hypotheses (Choudhury et al., Clinical Therapeutics, 2026, DOI (external link)). Two other systematic reviews agree that GLP-1 medications may reduce binge eating, but say large, blinded, placebo-controlled trials are still missing, so this shouldn't be treated as established therapy yet (Aoun et al., Journal of Clinical & Translational Endocrinology, 2024, DOI (external link); Carminati et al., International Clinical Psychopharmacology, 2025, DOI (external link)).
Two caveats go with that. First, "may help binge eating" is not the same as "safe for any eating disorder." The effect that could quiet binge urges is the same one that could deepen restriction in someone prone to it. Second, the Carminati review also noted reports linking these drugs to depressive symptoms and suicidal ideation in some people, and called that evidence preliminary and inconsistent (Carminati et al., International Clinical Psychopharmacology, 2025, DOI (external link)). Larger data since then are reassuring on that point. In January 2026, the FDA reported that a meta-analysis of 91 placebo-controlled trials with 107,910 patients found no increased risk of suicidal thoughts or behavior, and asked for that warning to be removed from the Saxenda, Wegovy and Zepbound labels (FDA Drug Safety Communication (external link)). As of September 2026, the Wegovy label lists the warning as removed in February 2026. Our guide to GLP-1 medications and depression covers that evidence in detail. Mood is still worth watching, but the trial data don't show a rise.
There is also a drug-safety reporting signal to know about. An analysis of the World Health Organization's global adverse-event database found that eating-disorder terms were reported disproportionately often with dulaglutide, semaglutide and liraglutide, at roughly four to seven times the expected rate (adjusted reporting odds ratios 4.17–6.80), even though overall psychiatric reporting was not raised (Nishida et al., Clinical Nutrition, 2025, DOI (external link)). Spontaneous reports can't show whether the medication triggered the problem, unmasked one that was already there, or simply got reported more because clinicians were watching for it. It is still one more reason for close monitoring, not wait-and-see, if you have an eating-disorder history.
An active eating disorder is a different situation
There's an important line between a history of and currently living with an eating disorder. An active eating disorder is not a listed contraindication on the drug labels, and there is no specific FDA warning about GLP-1 use in people with eating disorders. In practice, though, many clinicians are cautious with anyone who has or has had anorexia nervosa or atypical anorexia, and may avoid GLP-1s for people with current restrictive eating (ANAD, 2025 (external link)). Public-health researchers have called for closer monitoring of these drugs for misuse and harm in high-risk groups, naming people with eating disorders directly, and have warned against treating rapid weight loss itself as the goal (Peiper et al., Preventive Medicine, 2025, DOI (external link)). An appetite suppressant given during an active restrictive illness can speed up harm.
A history doesn't automatically close the door. It changes the question from "how much weight can I lose" to whether, and how, treatment fits into a recovery that's already in place.
This is a decision for a treatment team
The research keeps pointing to a process: screening before starting, and mental-health involvement during treatment. If you have any eating-disorder history, raise it before a prescription is written. Ideally your prescriber and a mental-health professional talk to each other. Our guide on raising this with a mental-health provider can help you start that conversation and set up check-ins through titration and weight loss. If family members with their own history are part of the picture, see talking to family when there's a history of disordered eating.
The aim is simple: someone who knows your history is watching for warning signs, so a "good drug response" and a relapse don't get confused.
Warning signs to watch for
During treatment, tell your providers if you notice any of these:
- Eating far less than your plan calls for, or skipping meals because "I'm just not hungry" has become a rule.
- Feeling relief or pride at eating less, or anxiety and guilt when you do eat.
- A pull to lose more weight than is medically recommended, or moving the goalposts each time you reach one.
- Old patterns coming back in a new form: rigid rules, food avoidance, compulsive weighing or body-checking.
- Growing preoccupation with your body, shape, or the number on the scale.
None of these is a reason for shame, or for quietly stopping your medication on your own. They're reasons to check in so the plan can be adjusted with support.
The bottom line
A past eating disorder doesn't rule out a GLP-1, but it calls for more screening and monitoring and a mental-health professional in the loop, while an active restrictive disorder calls for real caution before any weight-loss use.
Research findings above are attributed to peer-reviewed articles indexed in PubMed. This is general education, not medical or mental-health advice, and it can't tell you whether treatment is right for you. That decision belongs with you and a care team that includes a mental-health professional who knows your history.
If you're struggling with an eating disorder, the National Eating Disorders Association (external link) offers a free screening tool and help resources on its website. If you're in crisis or having thoughts of harming yourself, get help now. In the U.S., call or text 988 (Suicide & Crisis Lifeline), or text HOME to 741741 (Crisis Text Line).